1172 related articles for article (PubMed ID: 26337538)
41. Biologics for rheumatoid arthritis: an overview of Cochrane reviews.
Singh JA; Christensen R; Wells GA; Suarez-Almazor ME; Buchbinder R; Lopez-Olivo MA; Tanjong Ghogomu E; Tugwell P
Cochrane Database Syst Rev; 2009 Oct; 2009(4):CD007848. PubMed ID: 19821440
[TBL] [Abstract][Full Text] [Related]
42. Cost-effectiveness of TNF inhibitors vs synthetic disease-modifying antirheumatic drugs in patients with rheumatoid arthritis: a Markov model study based on two longitudinal observational studies.
Kvamme MK; Lie E; Uhlig T; Moger TA; Kvien TK; Kristiansen IS
Rheumatology (Oxford); 2015 Jul; 54(7):1226-35. PubMed ID: 25573840
[TBL] [Abstract][Full Text] [Related]
43. Immunogenicity of Biologics in Chronic Inflammatory Diseases: A Systematic Review.
Strand V; Balsa A; Al-Saleh J; Barile-Fabris L; Horiuchi T; Takeuchi T; Lula S; Hawes C; Kola B; Marshall L
BioDrugs; 2017 Aug; 31(4):299-316. PubMed ID: 28612180
[TBL] [Abstract][Full Text] [Related]
44. [Cost-minimization analysis of subcutaneous abatacept in the treatment of rheumatoid arthritis in Spain].
Ariza R; Van Walsem A; Canal C; Roldán C; Betegón L; Oyagüez I; Janssen K
Farm Hosp; 2014 Jul; 38(4):257-65. PubMed ID: 25137158
[TBL] [Abstract][Full Text] [Related]
45. Treatment patterns following discontinuation of adalimumab, etanercept, and infliximab in a US managed care sample.
Yeaw J; Watson C; Fox KM; Schabert VF; Goodman S; Gandra SR
Adv Ther; 2014 Apr; 31(4):410-25. PubMed ID: 24604700
[TBL] [Abstract][Full Text] [Related]
46. Cost-efficacy of biologic therapies for psoriatic arthritis from the perspective of the Taiwanese healthcare system.
Yang TS; Chi CC; Wang SH; Lin JC; Lin KM
Int J Rheum Dis; 2016 Oct; 19(10):1002-1009. PubMed ID: 26404916
[TBL] [Abstract][Full Text] [Related]
47. Analysis of drug and administrative costs allowed by U.S. Private and public third-party payers for 3 intravenous biologic agents for rheumatoid arthritis.
Wong BJ; Cifaldi MA; Roy S; Skonieczny DC; Stavrakas S
J Manag Care Pharm; 2011 May; 17(4):313-20. PubMed ID: 21534642
[TBL] [Abstract][Full Text] [Related]
48. Cost-Effectiveness of Secukinumab Versus Other Biologics in the Treatment of Psoriatic Arthritis: An Argentinean Perspective.
Aiello E; Bianculli PM; Bhattacharyya D; Gunda P; Citera G
Value Health Reg Issues; 2019 Dec; 20():86-94. PubMed ID: 31103950
[TBL] [Abstract][Full Text] [Related]
49. Use of biological drugs in patients with psoriasis and psoriatic arthritis in Italy: Results from the PSONG survey.
Potenza MC; Peris K; Berardesca E; Bianchi L; Richetta A; Bernardini N; De Simone C; Teoli M; Zangrilli A; D'epiro S; Orsini D; Narcisi A; Chimenti S; Costanzo A
Dermatol Ther; 2018 Jan; 31(1):. PubMed ID: 29215183
[TBL] [Abstract][Full Text] [Related]
50. National and regional dose escalation and cost of tumor necrosis factor blocker therapy in biologic-naïve rheumatoid arthritis patients in US health plans.
Joyce AT; Gandra SR; Fox KM; Smith TW; Pill MW
J Med Econ; 2014 Jan; 17(1):1-10. PubMed ID: 24131136
[TBL] [Abstract][Full Text] [Related]
51. Economic Impact of Above-Label Dosing with Etanercept, Adalimumab, or Ustekinumab in Patients with Psoriasis.
Feldman SR; Zhao Y; Zhou H; Herrera V; Tian H; Li Y
J Manag Care Spec Pharm; 2017 May; 23(5):583-589. PubMed ID: 28448778
[TBL] [Abstract][Full Text] [Related]
52. The comparative effectiveness of biologics among older adults and disabled rheumatoid arthritis patients in the Medicare population.
Yun H; Xie F; Delzell E; Chen L; Yang S; Saag KG; Joseph G; Harrison D; Curtis JR
Br J Clin Pharmacol; 2015 Dec; 80(6):1447-57. PubMed ID: 26130274
[TBL] [Abstract][Full Text] [Related]
53. Treatment Patterns Among Patients with Psoriatic Arthritis Treated with a Biologic in the United States: Descriptive Analyses from an Administrative Claims Database.
Walsh JA; Adejoro O; Chastek B; Palmer JB; Hur P
J Manag Care Spec Pharm; 2018 Jul; 24(7):623-631. PubMed ID: 29952704
[TBL] [Abstract][Full Text] [Related]
54. Golimumab for the treatment of psoriatic arthritis.
Yang H; Epstein D; Bojke L; Craig D; Light K; Bruce I; Sculpher M; Woolacott N
Health Technol Assess; 2011 May; 15 Suppl 1():87-95. PubMed ID: 21609657
[TBL] [Abstract][Full Text] [Related]
55. Tailored treatment options for patients with psoriatic arthritis and psoriasis: review of established and new biologic and small molecule therapies.
Elyoussfi S; Thomas BJ; Ciurtin C
Rheumatol Int; 2016 May; 36(5):603-12. PubMed ID: 26892034
[TBL] [Abstract][Full Text] [Related]
56. Treatment Switch Patterns and Healthcare Costs in Biologic-Naive Patients with Psoriatic Arthritis.
Wu JJ; Pelletier C; Ung B; Tian M; Khilfeh I; Curtis JR
Adv Ther; 2020 May; 37(5):2098-2115. PubMed ID: 32141018
[TBL] [Abstract][Full Text] [Related]
57. Treatment persistence of biologics among patients with psoriatic arthritis.
Haddad A; Gazitt T; Feldhamer I; Feld J; Cohen AD; Lavi I; Tatour F; Bergman I; Zisman D
Arthritis Res Ther; 2021 Jan; 23(1):44. PubMed ID: 33514410
[TBL] [Abstract][Full Text] [Related]
58. Clinical Outcomes and Biologic Costs of Switching Between Tumor Necrosis Factor Inhibitors in US Veterans with Rheumatoid Arthritis.
Cannon GW; DuVall SL; Haroldsen CL; Caplan L; Curtis JR; Michaud K; Mikuls TR; Reimold A; Collier DH; Joseph GJ; Harrison DJ; Sauer BC
Adv Ther; 2016 Aug; 33(8):1347-59. PubMed ID: 27352377
[TBL] [Abstract][Full Text] [Related]
59. Real-life 10-year retention rate of first-line anti-TNF drugs for inflammatory arthritides in adult- and juvenile-onset populations: similarities and differences.
Favalli EG; Pontikaki I; Becciolini A; Biggioggero M; Ughi N; Romano M; Crotti C; Gattinara M; Gerloni V; Marchesoni A; Meroni PL
Clin Rheumatol; 2017 Aug; 36(8):1747-1755. PubMed ID: 28597133
[TBL] [Abstract][Full Text] [Related]
60. Dose Modification in Biologic Therapy for Moderate to Severe Psoriasis: A Descriptive Analysis in a Clinical Practice Setting.
Baniandrés O; Rodríguez-Soria VJ; Romero-Jiménez RM; Suárez R
Actas Dermosifiliogr; 2015 Sep; 106(7):569-77. PubMed ID: 25935194
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
